Abstract:Introduction The vast pleiotropic effect of statins has intrigued many researchers to select them as potential candidates against bacterial infections. The role of statins against bacterial pathogens remains debatable. This study was undertaken to evaluate and compare the antibacterial effect of commonly available statins against the most frequently isolated bacterial pathogens causing respiratory tract infections in our tertiary care hospital using sputum as a sample. Materials and methods The study was conducted in the Microbiology Laboratory of our hospital. Drugs including atorvastatin, rosuvastatin, and simvastatin were purchased in pure form from Sigma Aldrich. Dimethylsulfoxide (DMSO) was used as a solvent for all three drugs. The positive controls used were gentamycin and amoxicillin for Gram-negative and Gram-positive bacteria, respectively. Data regarding all the culture and sensitivity results of sputum samples of patients admitted to the Respiratory Intensive Care Unit over the past 12 months were analyzed. The most common bacterial pathogens Staphylococcus aureus, Klebsiella pneumoniae, and Streptococcus pneumoniae isolated from sputum specimens were taken for our study. The antibacterial effect of statins was studied using two methods: the agar cup diffusion method and the broth dilution method. The zone of inhibition and minimum inhibitory concentration of the drugs were calculated and analyzed. Statistical analysis was performed using GraphPad Prism software version 10.2.0. A one-way ANOVA test was used to determine if there was any statistical difference between the different statins and antibiotic groups. An unpaired t-test was used to determine the statistical difference between the statins. Results and discussion For the agar cup diffusion method, our results displayed a lack of antibacterial activity of all three statins atorvastatin, rosuvastatin, and simvastatin against all three bacterial strains Staphylococcus aureus, Klebsiella pneumoniae, and Streptococcus pneumoniae after overnight incubation by agar cup method at concentrations of 3.125 μg/ml, 6.25 μg/ml, 12.5 μg/ml, 25 μg/ml and 50 μg/ml, respectively. The zone of inhibition observed was less than 4 mm (resistant) for all the serial dilutions of atorvastatin, rosuvastatin, and simvastatin. For the broth dilution method, the ANOVA test showed amoxicillin and gentamicin to have high statistically significant microbial growth inhibitory activity (p-value < 0.005) compared to atorvastatin and rosuvastatin. Statistically, though atorvastatin showed significant antimicrobial activity compared to normal saline and rosuvastatin, this was not considered clinically significant as the antimicrobial activity shown by atorvastatin was very negligible compared to the controls used and did not correspond to the serial dilutions of the drug. Conclusion Atorvastatin, rosuvastatin, and simvastatin lacked antibacterial activity against all three bacterial strains isolated from sputum specimens: Staphylococcus aureus, Klebsiella pneumoniae, and Streptococcus pneumoniae. Hence, the use of statins as an antimicrobial drug for respiratory tract infections has limited applications.

Repurposing simvastatin for treatment of Klebsiella pneumoniae infections: in vitro and in vivo study

Treatment with Atorvastatin Provides Additional Benefits to Imipenem in a Model of Gram-Negative Pneumonia Induced by Klebsiella pneumoniae in Mice

Statin-conferred enhanced cellular resistance against bacterial pore-forming toxins in airway epithelial cells

Statin adjunctive therapy shortens the duration of TB treatment in mice

Simvastatin increases the in vivo activity of the first-line tuberculosis regimen

Statins and oral biofilm: Simvastatin as a promising drug to control periodontal dysbiosis

Amelioration of Endotoxin-Induced Acute Lung Injury and Alveolar Epithelial Cells Apoptosis by Simvastatin Is Associated with Up-Regulation of Survivin/NF-kB/p65 Pathway

Anti-inflammatory effect of simvastatin by impeding TNF-α and interleukin-1ß pathways: antiangiogenic activity of simvastatin and simvastatin-loaded silver nanoparticles

Protective efficacy of statins in patients with <i>Klebsiella pneumoniae</i> bloodstream infection

Effects of statins on multispecies oral biofilm identify simvastatin as a drug candidate targeting Porphyromonas gingivalis

Therapeutic advancement of simvastatin-loaded solid lipid nanoparticles (SV-SLNs) in treatment of hyperlipidemia and attenuating hepatotoxicity, myopathy and apoptosis: Comprehensive study

Unveiling the Antibacterial Properties of Statins: An In Vitro Study on Helicobacter pylori

An In Vitro Study on the Antibacterial Activity of Statins Against the Most Common Bacterial Pathogens Causing Respiratory Tract Infections in a Tertiary Care Hospital

[Effects of simvastatin on airway inflammation and airway mucus hypersecretion in rats with chronic obstructive pulmonary disease].

Protective Effects of Simvastatin on Endotoxin-Induced Acute Kidney Injury through Activation of Tubular Epithelial Cells’ Survival and Hindering Cytochrome C-Mediated Apoptosis

Simvastatin Inhibits Endotoxin-Induced Apoptosis in Liver and Spleen Through Up-Regulation of Survivin/NF-κB/p65 Expression

Opposite effects of simvastatin on the bactericidal and inflammatory response of macrophages to opsonized S. aureus

Simvastatin decreases hyperbaric oxygen-induced acute lung injury by upregulating eNOS

Simvastatin attenuates radiation-induced murine lung injury and dysregulated lung gene expression.

Augmented simvastatin cytotoxicity using optimized lipid nanocapsules: a potential for breast cancer treatment

A Novel Chemosynthetic Peptide with Β-Sheet Motif Efficiently Kills Klebsiella Pneumoniae in a Mouse Model.